| Literature DB >> 26069577 |
Caroline Hoemann1, Rita Kandel2, Sally Roberts3, Daniel B F Saris4, Laura Creemers4, Pierre Mainil-Varlet5, Stephane Méthot6, Anthony P Hollander7, Michael D Buschmann1.
Abstract
Cartilage repair strategies aim to resurface a lesion with osteochondral tissue resembling native cartilage, but a variety of repair tissues are usually observed. Histology is an important structural outcome that could serve as an interim measure of efficacy in randomized controlled clinical studies. The purpose of this article is to propose guidelines for standardized histoprocessing and unbiased evaluation of animal tissues and human biopsies. Methods were compiled from a literature review, and illustrative data were added. In animal models, treatments are usually administered to acute defects created in healthy tissues, and the entire joint can be analyzed at multiple postoperative time points. In human clinical therapy, treatments are applied to developed lesions, and biopsies are obtained, usually from a subset of patients, at a specific time point. In striving to standardize evaluation of structural endpoints in cartilage repair studies, 5 variables should be controlled: 1) location of biopsy/sample section, 2) timing of biopsy/sample recovery, 3) histoprocessing, 4) staining, and 5) blinded evaluation with a proper control group. Histological scores, quantitative histomorphometry of repair tissue thickness, percentage of tissue staining for collagens and glycosaminoglycan, polarized light microscopy for collagen fibril organization, and subchondral bone integration/structure are all relevant outcome measures that can be collected and used to assess the efficacy of novel therapeutics. Standardized histology methods could improve statistical analyses, help interpret and validate noninvasive imaging outcomes, and permit cross-comparison between studies. Currently, there are no suitable substitutes for histology in evaluating repair tissue quality and cartilaginous character.Entities:
Keywords: animal models; articular cartilage; biopsy; cartilage repair; collagen type I; collagen type II; fibrocartilage; glycosaminoglycan; histology; polarized light microscopy; subchondral bone; tidemark
Year: 2011 PMID: 26069577 PMCID: PMC4300784 DOI: 10.1177/1947603510397535
Source DB: PubMed Journal: Cartilage ISSN: 1947-6035 Impact factor: 4.634
The Zonal Variation Seen in Articular Cartilage
| General Comments | Superficial Zone | Midzone | Deep Zone | |
|---|---|---|---|---|
| Cells | Chondrocyte morphology varies throughout depth of cartilage; no inflammatory cells present | Elongated, single, and aligned parallel to the surface | Rounded/oval and single | Rounded/oval cells; lacunae may be obvious; cells may be ordered into columns, depending on species, age, and location within joints but not in adult human knee/hip articular cartilage |
| Extracellular matrix | homogeneous in appearance; contains no blood vessels or nerves | Collagen fibers parallel to surface when visualized by PLM; smooth surface | No obvious collagen fiber orientation when viewed with PLM | Collagen fibers perpendicular to the tidemark when viewed with PLMExpresses mineralization-related molecules such as alkaline phosphatase in deep aspect close to the bone |
| Major matrix molecules | Collagen I | May be present in superficial layer | Absent | Absent (although reported sometimes in osteoarthritis in very lowest region) |
| Collagen II | Throughout; may be absent in few upper microns[ | Throughout | Throughout | |
| Proteoglycans (PGs): most abundant is aggrecan; demonstrable by IHC and/or metachromasia by staining with, for example, toluidine blue or safranin O; ratio of keratan sulfate (KS):chondroitin sulfate (CS) increases towards bone | Throughout; may be absent in few upper microns[ | Throughout | Throughout | |
| Calcified cartilage | Layer of calcified (mineralized) cartilage below the tidemark forms a collagen type II+ undulating interface between the articular cartilage and lamellar bone and contains round chondrocytes that express collagen type X; the tidemark (or mineralization front) is located between the calcified and noncalcified zones and is demonstrable in adults as a fine, basophilic line(s) on H&E staining; it is not completely characterized but contains calcium phospholipid[ | Collagen type II fibers from hyaline tissue extend into calcified cartilage |
Note: PLM = polarized light microscopy; IHC = immunohistochemistry; H&E = hematoxylin eosin.
Changes in osteoarthritis: initial denaturation seen here.[8]
Changes in osteoarthritis: initial loss of PGs seen here.[9,10]
Changes in osteoarthritis: vascular invasion of the tidemark from the subchondral bone[26] and reduplication of the tidemark is seen in aging and osteoarthritis.[11,12]
Figure 1.Different features of the osteochondral junction in normal and repair cartilage are revealed by hematoxylin and eosin (H & E) (A, C, E, G) and Safranin O/fast green/iron hematoxylin (SafO) (B, D, F, H). In normal human cartilage (A and B, adult hip surgical waste, femoral neck fracture), H&E clearly stains the tidemark (A, white arrows), while SafO readily discriminates cartilage from fast green–stained bone (below the black arrows, B). For heterogeneous human repair cartilage (C and D, biopsy taken 1 year postmicrofracture[71,121]), H&E is better for determining the cartilage-bone boundary (black arrows, C) and abnormal mineralization (dashed circle), while SafO discriminates fibrocartilage from fast green–stained fibrous repair and bone (D). In hyaline cartilage repair elicited in a sheep model (E-H, 6 months posttreatment[43]), the tidemark is beginning to form (white arrows, 10x magnification for E and F, 40x magnification for G and H). White arrows = tidemark; black arrows = cartilage-bone interface; AC = articular cartilage; cc = calcified cartilage; FC = fibrocartilage; HC = hyaline cartilage; b = bone.
Published Histological Analyses of Human Repair Cartilage
| Reference | Repair Procedure | Patient Number | % of Patients Analyzed | H | H/FC | FC | TT | F | Bone | Patient Age (y) | Repair Tissue Postoperative Time | Failure Rate | Collagen Characterization | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Waste or Biopsy of Failed Repair | Sample ( | |||||||||||||||
| Insall | 1967 | Drilling | 12 | 1 | 8% | 100% | 56 ± 8 | 4.9 ± 2.3 y | 25% at 3-7 y | |||||||
| Nehrer | 1999 | Abrasion | — | 12 | 42% | 17% | 25% | 10% | 20% | 0% | 39 ± 9 | 1 mo to 19 y (mean, 4 y) | — | I, II, X | ||
| Nehrer[ | 1999 | Periosteal graft | — | 4 | 25% | 75% | 0% | 0% | 0% | (OG75%) | 40 ± 9 | 5 mo to 10 y (mean, 5 y) | — | I, II, X | ||
| Nehrer[ | 1999 | ACI (salvage) | — | 6 | 0% | 0% | 0% | 30% | 70% | 0% | 38 ± 9 | 25 mo to 7 y (mean, 4 y) | — | I, II, X | ||
| Bouwmeester[ | 1999 | Perichondrial graft | 88 | 22 | 24% | 29% | 24% | 24% | 24% | 29 ± 9 | 5-61 mo (mean, 21 mo) | 24% at 2 y | I, II, X | |||
| Biopsies: Unblinded Analysis | Biopsies ( | H | H/FC | FC | TT | F | Bone | |||||||||
| Hangody | 1997 | Mosaic | 44 | 6 | 14% | 100% | N/A | 3 mo to 3.5 y | Picrosirius, PLM | |||||||
| Roberts[ | 2003 | ACI + mosaic | 6 | 50% | 50% | 0% | 35 ± 10 | 9-34 mo | I, II, III, VI, X, PLM | |||||||
| Roberts[ | 2003 | ACI | 14 | 14% | 43% | 43% | 35 ± 10 | 9-34 mo | I, II, III, VI, X, PLM | |||||||
| Marcacci[ | 2005 | Hyalograft C | 107 | 22 | 21% | 55% | 27% | 18% | N/A | 10-30 mo (mean, 15 mo) | ||||||
| Henderson[ | 2005 | ACI | 53 | 20 | 35% | 65% | 15% | 20% | N/A | 7-24 mo (mean, 13 mo) | ||||||
| Tins | 2005 | ACI | 41 | 41 | 100% | 10% | 24% | 61% | 5% | 35 (18-53) | 12 mo | PLM | ||||
| Hollander[ | 2006 | Hyalograft C | 23 | 43% | 13% | 43% | 36 (13-54) | 6-30 mo (mean, 16 mo) | I, II (biochem) | |||||||
| Biopsies: Prospective Study, No Control Group | Biopsies ( | H | H/FC | FC | TT | F | Bone | |||||||||
| Briggs[ | 2003 | ACI - Chondroguide | 14 | 13 | 93% | 46% | 15% | 23% | 15% | 30 (16-51) | 11 ± 4 mo | II, X, PLM | ||||
| Bartlett | 2004 | MACI | 47 | 11 | 23% | 27% | 9% | 64% | 33 (17-47) | 12 mo | II, IIa, X | |||||
| Bartlett | 2004 | ACI-C | 44 | 14 | 32% | 29% | 14% | 57% | 34 (15-49) | 12 mo | PLM | |||||
| Moriya[ | 2007 | ACI (on OCD) | 6 | 6 | 100% | 0% | 67% | 33% | 0% | 20 (13-35) | 12 mo | I, II | ||||
| Gikas | 2009 | ACI, ACI-C, MACI | 248 | 248 | 100% | 24% | 27% | 46% | 4% | 33 (15-52) | 3-55 mo (mean, 15 mo) | PLM | ||||
| Biopsies: RCT, Blinded Analysis with Control | Biopsies ( | ICRS-II | H | H/FC | FC | TT | F | Bone | ||||||||
| Knutsen[ | 2005 | MFX | 40 | 35 | 88% | 11% | 17% | 51% | 20% | 18-45 | 24 mo | 23% at 5 y | PLM | |||
| Knutsen[ | 2005 | ACI | 40 | 32 | 80% | 19% | 31% | 34% | 16% | 18-45 | 24 mo | 23% at 5 y | PLM | |||
| Saris | 2008 | MFX | 61 | 36 | 59% | ~46% | 18-50 | 12 mo | 12% at 3 y | II | ||||||
| Saris | 2008 | CCI | 57 | 46 | 81% | ~55% | 18-50 | 12 mo | 4% at 3 y | II | ||||||
Note: H = hyaline; H/FC = hyaline mixed with fibrocartilage; FC = fibrocartilage; F = fibrous tissue; TT = transitional tissue; PLM = polarized light microscopy; I, II, IIa, III, VI, X = collagen type; — = not applicable; OG75 = bone overgrowth was seen in 75% of the treated defects; N/A = information not available specifically for biopsied patients (all patients were between 17 to 64 years old); ACI = autologous chondrocyte implantation; MACI = matrix autologous chondrocyte implantation; CCI = characterized chondrocyte implantation; ICRS-II = ICRS-II overall histological score. References: Insall,[64] Nehrer et al.,[67] Bouwmeester et al.,[66] Roberts et al.,[96] Marcacci et al.,[84] Henderson et al.,[83] Tins et al.,[76] Hollander et al.,[70] Briggs et al.,[62] Bartlett et al.,[99] Moriya et al.,[72] Gikas et al.,[59] Knutsen et al.,[56,57] and Saris et al.[61,98]
Hyaline defined as >60% tissue with hyaline character.
Hyaline defined as >50% tissue with hyaline character.
Biopsies were taken only when a partial failure was present or a clear failure (fibrocartilage, loose flap, loose body).
Condylar, trochlear, and patellar biopsies.
Two-millimeter biopsies were taken with a Giebel needle from central and marginal areas of the graft.
Biopsies from painful knees were excluded.
Two 3-mm Jamshidi biopsies were collected from each treated lesion.
Two biopsies were collected with an 11-gauge needle: one from the central lesion and one from the same lateral condyle (nonlesional).
Guidelines for Histological Processing and Analyses of Repair
| 1. Lesion size and location |
Human: 2-mm diameter, ~1-cm deep biopsy from estimated geometric center of initial lesion, perpendicular to surface. Sample includes bone, full-thickness repair. Animal: sample block includes entire defect, flanking articular cartilage, subchondral bone encompassing potential regions of bone resorption. |
| 2. Timing of biopsy and sample recovery |
|
Human biopsy: 12-month or 24-month outcome, one biopsy per lesion. Macroscopic ICRS score. Video document and detailed description of biopsy site. Animal: acute defect (0-3 days) and long-term repair: ≥2 months (rabbit) or ≥6 months (large animal), with and without treatment. Exact endpoints can be tailored to individual studies and should provide information on the rate of implant incorporation or degradation in the joint. Macroscopic score (whole joint). Take any biochemistry or biomechanics samples prior to tissue fixation. |
| 3. Histoprocessing (for cartilage-bone analysis) |
|
Fixation in 10% normal buffered formalin or buffered 4% paraformaldehyde. Human: decalcify biopsies with bone for ~30 hours in 0.5 N HCl/0.1% glutaraldehyde[ Animal: decalcify ~10 days (rabbit distal femur) or weeks (large animal samples) in 0.5 N HCl (with or without 0.1% glutaraldehyde)[ For each specimen, collect serial sections from at least 2 predetermined levels (fixed distance to each other in the repair tissue). 5-µm paraffin sections (human, sheep, horse) or 8- to 10-µm cryosections (rabbit) for collagen typing. Stain 2 serial sections from each level (for each stain). Tissue sections processed separately for electron microscopic analysis of matrix (optional). |
| 4. Staining |
|
H&E (cartilage-bone interface, cell morphology, tidemark, abnormal calcification). Safranin O or toluidine blue (glycosaminoglycan content). Collagen immunostaining for collagen type I and type II. Unstained sections (for polarized light microscopy [PLM]). Recut and stain any torn, folded, or poorly stained sections. Verify complete set of sections (use the best section free of folds, tears). Blind sections or digital scans prior to scoring. |
| 5. Evaluation methods[ |
|
Must be performed by 2 or 3 trained and blinded observers. Blinded consensus for outlier scores. Determine implant presence/absence. |
As our understanding of cartilage repair and chondrocyte biology improves, these recommendations may have to be modified.
Figure 2.Appearance of human 2-mm-diameter biopsy obtained with a Jamshidi 11-gauge needle (A, C) and corresponding decalcified Safranin O–stained paraffin section (B, D). Samples were obtained ex vivo with an ethics-approved protocol from the same lateral condyle (nonlesional area) obtained after total knee arthroplasty (74-year-old female). (A and B) A biopsy cored perpendicular to the surface and (C and D) a biopsy cored deliberately at an oblique angle to the surface are shown. Both biopsies were initially 6 mm long, but the subchondral bone was missing from the oblique biopsy prior to histoprocessing (C). Part of the subchondral bone in the perpendicular biopsy (B) was lost during histoprocessing.
Figure 3.Histoprocessing and histomorphometry of large animal defects. The example is taken from a sheep cartilage repair model (6 months repair[43]). In this unilateral cartilage repair model, the repaired defect (top panels) was decalcified, trimmed at 2 levels in the defect (midproximal and middistal), and stained with Safranin O/Fast Green. Repair tissue above the projected tidemark was cropped using histomorphometric software, and total area (TA) and total stained repair tissue area (TS) were used to determine percentage of Safranin O–stained repair. The contralateral intact condyle was decalcified, trimmed through the middle, and cropped with matching defect width, and total area was used to determine percentage fill of the defect with repair tissue.
Figure 4.Example of standardized histoprocessing to evaluate a human biopsy (A-D, from cadaveric knee medial femoral condyle) or sheep hyaline repair cartilage 6-month repair after treatment with microfracture and chitosan-GP/blood implant (E-H).[43] Sections were stained for Safranin O, immunostained for collagen type II and collagen type I, and observed by polarized light microscopy (PLM). SZ = superficial zone; DZ = deep zone; AC = articular cartilage. Note the abnormal vascular invasion and mineralization (*) in this particular human biopsy above the tidemark (horizontal arrow, A-D), which is frequently observed in osteoarthritis.[21]
Figure 5.Histomorphometry of chondral versus subchondral soft repair tissues. The example is from a 2-month repair of a trochlear full-thickness rabbit knee defect with two 0.9-mm microdrill holes.[44] (A) Safranin O–stained trochlear repair tissue, with the “projected tidemark” drawn through the defect area. (B) The chondral repair is cropped separately from the subchondral soft tissue repair for further histomorphometric analysis.